-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] What major events happened in the pharmaceutical industry in April? The author sorted out and found that a large number of pharmaceutical companies have held meetings, repurchased shares, and resigned, which are worth reviewing
.
[After the meeting] Since April, many pharmaceutical companies have achieved IPO after the meeting
.
Hongbo Pharmaceutical: IPO passed the meeting On April 21, the results of the 21st review meeting of the GEM Listing Committee in 2022 were announced, and the first IPO of Hongbo Pharmaceutical was approved
.
This time, the company plans to raise 477.
07 million yuan, and the number of raised investment projects is 2, which are the construction projects of preclinical new drug research and development bases and supplementary working capital
.
United Imaging Medical: The application for listing on the Science and Technology Innovation Board has been reviewed and approved On April 15, the 29th review meeting of the Shanghai Stock Exchange Science and Technology Innovation Board Listing Committee in 2022 was held.
Information Disclosure Requirements
.
Nuocheng Jianhua: The application for listing on the Science and Technology Innovation Board was approved On April 13, Nuocheng Jianhua announced that the company's application for listing on the Science and Technology Innovation Board was approved
.
It is reported that the company is an innovative drug company focusing on the independent research and development of drugs for malignant tumors and autoimmune diseases.
It was previously listed on the Hong Kong Stock Exchange in March 2020
.
The listing of Nuocheng Jianhua on the Science and Technology Innovation Board plans to raise 4 billion yuan, of which half of the funds will be used for new drug research and development
.
[Repurchase] Since April, listed pharmaceutical companies have been enthusiastic about repurchase
.
Among the repurchase plans disclosed by Shenzhen-listed companies, many companies plan to repurchase funds exceeding 1 billion yuan, including Yunnan Baiyao
.
Yunnan Baiyao: It plans to repurchase the company's shares with no more than 1.
1 billion yuan Yunnan Baiyao announced at noon on April 8 that the company plans to use no more than 1.
1 billion yuan of its own funds to repurchase the company's shares for the implementation of employee stock ownership plans or equity incentive plans
.
The upper limit of the repurchase shares is 9 million shares, accounting for 0.
7016% of the company's current total share capital.
The lower limit of the repurchase shares is 4.
5 million shares, accounting for 0.
3508% of the company's current total share capital.
The repurchase price does not exceed 124.
38 yuan per share
.
Tigermed: 39.
924 million yuan to repurchase company shares Tigermed announced at the end of April that on April 28, 2022, the company spent about RMB39.
924 million to repurchase 467,900 A shares
.
Hengrui Medicine: The first repurchase of 750,000 shares Hengrui Medicine announced on April 26 that on April 25, 2022, the company repurchased 750,000 shares for the first time through a centralized bidding transaction, and the repurchased shares accounted for the company's total.
The proportion of share capital is 0.
01%, the highest transaction price is 30.
18 yuan per share, the lowest price is 29.
71 yuan per share, and the total amount paid is about 22.
39 million yuan
.
[Resignation] In the context of the major changes in the pharmaceutical market environment, pharmaceutical companies are facing the pain of transformation, and the personnel changes of pharmaceutical company executives have become the norm
.
Since April, a large number of executives of pharmaceutical companies have reported leaving news
.
Jiahe Bio: President resigns and resigns On April 14, Jiahe Bio announced that due to spending more time on other affairs, Zhou Xinhua decided to submit his resignation as executive director, effective April 15, 2022
.
Zhou Xinhua also resigned from the position of president of the group
.
Jointown: Many executives have resigned due to changes At the end of April, Jointown announced that the company had undergone a number of personnel changes
.
Among them, Liu Yichang resigned from the position of general manager due to personal reasons, and the resignation time is April 23, 2022
.
In addition, Lin Xinyang also resigned as the secretary of the board of directors on April 23, 2022.
The reason for his resignation is: due to personal and work adjustment reasons
.
Hengrui Medicine: Deputy General Manager Resigns In April, Hengrui Medicine announced that Zou Jianjun, the company's deputy general manager, applied for his resignation as the company's deputy general manager for personal reasons
.
According to the data, Zou Jianjun has been deeply involved in oncology and served as the head of related businesses of Bayer China, Celgene, and Hengrui Medicine.
He joined Hengrui Medicine in September 2015 and has worked in Hengrui Medicine for more than six years
.
.
[After the meeting] Since April, many pharmaceutical companies have achieved IPO after the meeting
.
Hongbo Pharmaceutical: IPO passed the meeting On April 21, the results of the 21st review meeting of the GEM Listing Committee in 2022 were announced, and the first IPO of Hongbo Pharmaceutical was approved
.
This time, the company plans to raise 477.
07 million yuan, and the number of raised investment projects is 2, which are the construction projects of preclinical new drug research and development bases and supplementary working capital
.
United Imaging Medical: The application for listing on the Science and Technology Innovation Board has been reviewed and approved On April 15, the 29th review meeting of the Shanghai Stock Exchange Science and Technology Innovation Board Listing Committee in 2022 was held.
Information Disclosure Requirements
.
Nuocheng Jianhua: The application for listing on the Science and Technology Innovation Board was approved On April 13, Nuocheng Jianhua announced that the company's application for listing on the Science and Technology Innovation Board was approved
.
It is reported that the company is an innovative drug company focusing on the independent research and development of drugs for malignant tumors and autoimmune diseases.
It was previously listed on the Hong Kong Stock Exchange in March 2020
.
The listing of Nuocheng Jianhua on the Science and Technology Innovation Board plans to raise 4 billion yuan, of which half of the funds will be used for new drug research and development
.
[Repurchase] Since April, listed pharmaceutical companies have been enthusiastic about repurchase
.
Among the repurchase plans disclosed by Shenzhen-listed companies, many companies plan to repurchase funds exceeding 1 billion yuan, including Yunnan Baiyao
.
Yunnan Baiyao: It plans to repurchase the company's shares with no more than 1.
1 billion yuan Yunnan Baiyao announced at noon on April 8 that the company plans to use no more than 1.
1 billion yuan of its own funds to repurchase the company's shares for the implementation of employee stock ownership plans or equity incentive plans
.
The upper limit of the repurchase shares is 9 million shares, accounting for 0.
7016% of the company's current total share capital.
The lower limit of the repurchase shares is 4.
5 million shares, accounting for 0.
3508% of the company's current total share capital.
The repurchase price does not exceed 124.
38 yuan per share
.
Tigermed: 39.
924 million yuan to repurchase company shares Tigermed announced at the end of April that on April 28, 2022, the company spent about RMB39.
924 million to repurchase 467,900 A shares
.
Hengrui Medicine: The first repurchase of 750,000 shares Hengrui Medicine announced on April 26 that on April 25, 2022, the company repurchased 750,000 shares for the first time through a centralized bidding transaction, and the repurchased shares accounted for the company's total.
The proportion of share capital is 0.
01%, the highest transaction price is 30.
18 yuan per share, the lowest price is 29.
71 yuan per share, and the total amount paid is about 22.
39 million yuan
.
[Resignation] In the context of the major changes in the pharmaceutical market environment, pharmaceutical companies are facing the pain of transformation, and the personnel changes of pharmaceutical company executives have become the norm
.
Since April, a large number of executives of pharmaceutical companies have reported leaving news
.
Jiahe Bio: President resigns and resigns On April 14, Jiahe Bio announced that due to spending more time on other affairs, Zhou Xinhua decided to submit his resignation as executive director, effective April 15, 2022
.
Zhou Xinhua also resigned from the position of president of the group
.
Jointown: Many executives have resigned due to changes At the end of April, Jointown announced that the company had undergone a number of personnel changes
.
Among them, Liu Yichang resigned from the position of general manager due to personal reasons, and the resignation time is April 23, 2022
.
In addition, Lin Xinyang also resigned as the secretary of the board of directors on April 23, 2022.
The reason for his resignation is: due to personal and work adjustment reasons
.
Hengrui Medicine: Deputy General Manager Resigns In April, Hengrui Medicine announced that Zou Jianjun, the company's deputy general manager, applied for his resignation as the company's deputy general manager for personal reasons
.
According to the data, Zou Jianjun has been deeply involved in oncology and served as the head of related businesses of Bayer China, Celgene, and Hengrui Medicine.
He joined Hengrui Medicine in September 2015 and has worked in Hengrui Medicine for more than six years
.
